Completed OBSERVATIONAL NCT03243604

cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study (ARBITRAGE)

Cardiotoxicity of Abiraterone in the National French Pharmacovigilance Database and in the European Clinical Trials Database (EudraCT)

Sponsor: Groupe Hospitalier Pitie-Salpetriere

Conditions Arrhythmias, Cardiac Atrial Fibrillation and Flutter Cardiac Failure Tachycardia, Supraventricular

Interventions L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)

Updated 7 times since 2017 Last updated: Oct 17, 2018 Started: May 16, 2017 Primary completion: Jul 13, 2017 Completion: Jul 13, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Arrhythmias, Cardiac and Atrial Fibrillation and Flutter, this trial is completed. The trial is conducted by Groupe Hospitalier Pitie-Salpetriere and has accumulated 7 data snapshots since 2017. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Nov 2018 — Jan 2021 [monthly]

Completed
Jun 2018 — Nov 2018 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Sep 2017 — Apr 2018 [monthly]

Completed NA

First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Groupe Hospitalier Pitie-Salpetriere

Data source: Groupe Hospitalier Pitie-Salpetriere

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France